U.S. FDA Approves VYNDAQEL and VYNDAMAX for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
NEW YORK--(BUSINESS WIRE)--May 6, 2019--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL (tafamidis meglumine) and…
